Supplementary material to article by A. Batycka-Baran "Soluble Receptor for Advanced Glycation End Products: A Novel Biomarker for Psoriasis Severity with Therapeutic Implications?"

Table SI. Clinical characteristics of the study group

	Patients with chronic plaque psoriasis $n = 65$	Controls $n = 35$
Sex, female/male, n (%)	28 (43.1)/37 (56.9)	16 (45.7)/19 (54.3)
Age, years, mean±SD	48.33±17.95	46.41 ± 14.11
Disease duration, years, mean ± SD [range]	14.35±13.32 [0.8-47]	
PASI, mean±SD	14.23±7.07	
BMI, mean±SD	27.89 ± 15.94	26.76 ± 13.74
Hypertension, n (%) ^a		
Total	21 (32.31)	10 (28.57)
Use of hypotensive therapy	18 (27.69)	9 (25.71)
Dyslipidaemia, n (%) ^b		
Total	11 (16.92)	5 (14.28)
Use of lipid-lowering therapy	9 (13.85)	5 (14.28)
Obesity, n (%) ^c	12 (18.46)	5 (14.28)
Smoking habit, n (%) ^d	18 (25.69)	6 (17.14)

^aSystolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive medication. ^bElevated level of: total cholesterol and/or low-density lipoprotein cholesterol and/or triglycerides and/or use of lipid-lowering therapy. ^cSubjects with body mass index (BMI) ≥ 30. ^dSmoking at least 1 cigarette per day during the last 6 months. SD: standard deviation; PASI: Psoriasis Area and Severity Index.